{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:08:38Z","timestamp":1791544118217,"version":"4.3.4"},"reference-count":43,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T00:00:00Z","timestamp":1682553600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Cutan Pathol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>PRAME (PReferentially expressed Antigen in MElanoma) is a tumor\u2010associated antigen that has been studied in various cutaneous melanocytic lesions. p16, on the other hand, has been proposed to aid in distinguishing between benign and malignant melanocytic neoplasms. Studies on the diagnostic utility of PRAME and p16 in combination in differentiating nevi from melanoma are limited. We aimed to assess the diagnostic utility of PRAME and p16 in melanocytic tumors and their role in distinguishing between malignant melanomas and melanocytic nevi.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a single\u2010center retrospective cohort analysis over a 4\u2010year period (2017\u20132020). We used the pathological database of malignant melanomas (77 cases) and melanocytic nevi (51 cases) specimens from patients who underwent shave\/punch biopsies or surgical excisions and evaluated immunohistochemical staining percentage positivity and intensity for PRAME and p16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Most malignant melanomas showed positive\/diffuse PRAME expression (89.6%); on the other hand, 96.1% of nevi did not express PRAME diffusely. p16 was expressed consistently in nevi (98.0%). However, p16 expression in malignant melanoma was infrequent in our study. PRAME had a sensitivity and specificity of 89.6% and 96.1%, respectively, for melanomas versus nevi; on the other hand, p16 had a sensitivity and specificity of 98.0% and 28.6%, respectively, for nevi versus melanoma. Also, a PRAME+\/p16\u2212 melanocytic lesion is unlikely to be a nevus where most nevi were PRAME\u2212\/p16+.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In conclusion, we confirm the potential utility of PRAME and p16 for distinguishing melanocytic nevi from malignant melanomas.<\/jats:p><\/jats:sec>","DOI":"10.1111\/cup.14438","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T06:35:05Z","timestamp":1682663705000},"page":"763-772","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Potential diagnostic utility of <scp>PRAME<\/scp> and p16 immunohistochemistry in melanocytic nevi and malignant melanoma"],"prefix":"10.1111","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-2595","authenticated-orcid":false,"given":"Hisham F.","family":"Bahmad","sequence":"first","affiliation":[{"name":"The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine Mount Sinai Medical Center  Miami Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2728-9081","authenticated-orcid":false,"given":"Kei Shing","family":"Oh","sequence":"additional","affiliation":[{"name":"The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine Mount Sinai Medical Center  Miami Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1920-7901","authenticated-orcid":false,"given":"John","family":"Alexis","sequence":"additional","affiliation":[{"name":"The Arkadi M. Rywlin M.D. Department of Pathology and Laboratory Medicine Mount Sinai Medical Center  Miami Beach Florida USA"},{"name":"Department of Pathology, Herbert Wertheim College of Medicine Florida International University  Miami Beach Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,27]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80426-4"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2217\/bmm.12.65"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.244"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.16"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2016.12.006"},{"key":"e_1_2_10_7_1","first-page":"4090","article-title":"Heterogeneous expression of the tumor\u2010associated antigens RAGE\u20101, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T\u2010cell\u2010based immunotherapies?","volume":"58","author":"Neumann E","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0813"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.08.120"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9977"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8828579"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-019-0335-4"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12123612"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.07.045"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000068"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30385"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-16-0958"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001134"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13958"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970220)74:1<26::AID-IJC5>3.0.CO;2-2"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008390-200212000-00003"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153105"},{"key":"e_1_2_10_23_1","first-page":"331","article-title":"Deletion in p16INK4a and loss of p16 expression in human skin primary and metastatic melanoma cells","volume":"24","author":"Zhang H","year":"2004","journal-title":"Int J Oncol"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.033"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0560.2008.01154.x"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13876"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12092197"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13153864"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21608"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001393"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3218"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24808"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.0901a03"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1997.3824"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600862"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1197"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng0994-15"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13721"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/348417"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12186"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13000-015-0431-9"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.14130"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-022-01026-6"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0000000000002156"}],"container-title":["Journal of Cutaneous Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cup.14438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T04:22:56Z","timestamp":1692246176000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cup.14438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,27]]},"references-count":43,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/cup.14438"],"URL":"https:\/\/doi.org\/10.1111\/cup.14438","archive":["Portico"],"relation":{},"ISSN":["0303-6987","1600-0560"],"issn-type":[{"value":"0303-6987","type":"print"},{"value":"1600-0560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,27]]},"assertion":[{"value":"2022-09-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}